Elizabeth Bruckheimer

Dr. Bruckheimer is a Drug Development Advisor at Systems Oncology, as well as Vice President of Drug Development at Cancer Prevention Pharmaceuticals (CPP). Her professional career spans 20 years in oncology research, the biotech/ pharmaceutical industry, and contract research organizations. In those endeavors, she led cross-functional preclinical and translational drug development programs, laboratory and organizational operations, project management, and business development activities. Dr. Bruckheimer is currently the VP of Drug Development at Cancer Prevention Pharmaceuticals. Previously, she served as Vice President of Scientific Operations at Champions Oncology leading the development of its TumorGraft™ platform and oversaw all scientific operations and project management for Champions’ Translational Oncology Solutions division. Prior to that, Dr. Bruckheimer served as Associate Director and Manager at Systems Medicine, LLC., Senior Scientist at MedImmune, Inc., and Scientist II at Targeted Genetics Corporation where she led the pre-clinical and translational research programs and supported business development opportunities for these organizations. Her expertise and research interests include translational research, oncology drug development, and personalized medicine.

Dr. Bruckheimer received her Ph.D. from the University of Texas Graduate School of Biomedical Sciences and MD Anderson Cancer Center in Houston, Texas.